Avacta Share Discussion Threads

[pwhite73] 04/6/2024 09:52

Rajraj b "You sure about this?"

100% sure. It's called a local anaesthetic but its not really local at all that's why you can't smile with one half of your face when the dentist gives you an injection into your gum before drilling into your tooth. The local anaesthetic spreads across the whole area.

Now a peptide that could localise the drug solely to the tooth nerve, we're talking big money here.

I've been investing in pharma stocks over many years and know what I'm talking about.

I do believe you are beginning to understand what's going on now. How does the peptide work. How it is able to keep AVA6000 inert until it comes into contact with FAP. The results are meaningless until AVCT says to the pharma industry - "here is the proof if you don't believe us try it for yourselves".

If the pharma industry endorses the functionality of the AVA6000 peptide bids of £100s of millions would come in for the peptide alone. Its applications would be limitless.

[pwhite73] 04/6/2024 07:52

05:15 - 05:19 "With that peptide attached to it, it can't get into cells." - Dr Christina Coughlin.

Yes Dr Coughlin but the question the pharmaceutical industry wants to know is how does the peptide work at the molecular structural level. If such a peptide existed it could be deployed on a whole host of other drugs.

Take dental surgery for instance. When the dental surgeon injects a local anaesthetic into your back tooth half your face goes numb. This is because the drug gets into the bloodstream and has the same affect across half your face as it does on the nerve in your back tooth. Now imagine if the numbing effect was localised purely to the nerve in the tooth. People could return to work immediately as opposed to having to wait until the effects of the drug wears off.

The June interview and webinar has given temporary relief to the falling share price but it won't last. It's not PI shareholders AVCT need to convince at this late stage its the pharmaceutical industry.

Come on Dr Coughlin publish the research paper and subject it to academic peer review. Powerpoint and Excel are not going to save the company as a stand alone unit.

[fieldhouse] 03/6/2024 19:11

It works !!

I guess owf will disagree with his expert knowledge!!

[amanitaangelicus] 03/6/2024 16:41

Impressive.Just in case the mkt has misunderstood this info, Whitey ,our resident, 3 CSE scientist will explain. Phew, aint we lucky. Timed to halt the share price slump of course, but hey ho. Smith will be admiring the document from his nda bunkroom. Good day for the faithful.

[vertizeasun] 03/6/2024 15:33

Christina Coughlin
@coughlin582
Two figures in the AVA6000 data critical to the mechanism of a preCISION therapy. The doses of dox being delivered are 3-4x higher than standard dose with tumor concentration

Bringing the experts to explain these data in this #AVCT R&D Spotlight

[rajraj b] 03/6/2024 15:25

More 'lies' for PWhite to get his teeth into.

[vertizeasun] 03/6/2024 15:19

Updated today:

[dudishes] 03/6/2024 11:24

Goodness, so many experts!

The answer lies in the soil!

[pwhite73] 03/6/2024 10:25

Rajraj b - Yes I still do. AVCT has just raised £28 million. It is my opinion they are not going to waste anymore money on the never ending AVA6000 Phase 1 trials. AVCT needs to boost the share price or they can't meet their loan obligations without totally destroying what's left of shareholder value.

AVCT and SOFIE are both looking at the use of FAP to kill cancer cells. AVCT as a means of recognition and SOFIE as a means of inhibition.

RNS 28/03/24 - "This sub-study represents an ongoing collaboration between Avacta and SOFIE, in the use of [18F]FAPI-74 PET as a complementary diagnostic. [18F]FAPI-74 PET is currently in clinical development and for investigational use only."

So we know they have been working together prior to the date of the RNS. A full joint venture to kill cancer cells will perhaps give AVCT the boost they so desperately need.

[1347] 03/6/2024 09:58

Reminds me of the one with Cytiva, but there have been quite a few others.

[rajraj b] 03/6/2024 09:57

PWhite-"It is clear to me that AVCT has now partnered with SOFIE to seek a more plausible route into Phase 2 via the inhibition of FAP." You still believe this?

[pwhite73] 03/6/2024 09:31

1347 - It's not just a question of dragging out Phase 1. The collaborations with real biotech companies is to confer legitimacy on the company.

As Rajraj b said SOFIE would have to be in cahoots with the fraud, but of course they are not. AVCT are simply paying them for their services and in announcing a collaboration confers legitimacy on AVA6000.

But they are not fooling me.

[1347] 03/6/2024 09:16

I suggest people go and check just how many collaborations Avacta have had over the years, all were promising and so far none have gone very far at all, or have fallen by the wayside completely.

My view is that Avacta are just stretching out the Phase 1 as long as they can, because if AVA6000 were safe and and at least as effective than the current SoC it wouldn't be crawling along at this speed would it. Meanwhile the death spiral finance will kill the SP, slowly but surely.

[rajraj b] 02/6/2024 23:14

Unless, of course, SOFIE are in cahoots with AVCT to perpetuate these so called lies as suggested by PWhite.

[rajraj b] 02/6/2024 23:10

https://sofie.com/wp-content/uploads/2024/05/SOFIE-FAP-Webinar-2024.pdfThis is off the SOFIE site. Slides dedicated to the collaboration with AVCT using SOFIE FAP diagnostic tools in the AVCT trial. Note PWhite- it's for the diagnostic purposes in identifying FAPa rich sites quickly. Not for any other nonesense you were going on about. Hope that makes sense.

[pwhite73] 02/6/2024 22:27

Doxorubicin is one of the most if not the most powerful cancer cells killing drugs on the market. The problem is its toxicity. Any more than 500mg in total and it starts attacking healthy cells including the heart.

A British company claims it has invented a peptide warhead that can deliver 3.5 times the normal dosage of Doxorubicin and the toxicity effect is less than delivering Doxorubicin on its own and the maximum dosage has STILL not being determined even after 3.5 times!!!.

Yet the whole global pharmaceutical industry has totally ignored the British company and its claims to the point where the company can only seek finance from bucket shops with the CEO eventually resigning from nearly 20 years work.

I am right about the claims this company is making. Watch and learn.

[pwhite73] 02/6/2024 22:14

Rajraj b - "I’m sorry but that is extremely poor on your part."

No its not poor on my part for we are not dealing with some tinpot AIM oil explorer claiming test results have proven 2 billion barrels of oil in situ. We are dealing with clinical trials here.

The company must publish research papers and subject them to academic peer review if they are to be believed. My whole case rests around this. You claim they are teaming up with SOFIE for additional FAP diagnostics support. This is what peer review looks like.



"This study has been supported by SOFIE by the provision of precursors for FAPI synthesis"



"SOFIE licensed the FAPI-compounds from Heidelberg and Clovis Oncology and the tracer FAP-2286 from 3B Pharmaceuticals, both at an early stage of development"



"FLG is a FAPI co-inventor and is an advisor at Telix Pharma, SOFIE, ABX, and Alpha Fusion and receives royalties from iTheranostics and SOFIE Biosciences. The other authors declare no conflict of interest."

After three years AVA6000 still can't go down this road because they would have to prove how the £billion peptide warhead which is the Holy Grail for cancer works at the molecular structural level. They can't so what you get instead are unsubstantiated data results.

You either believe them or you don't. I DON'T.

[king suarez] 02/6/2024 21:38

"KS - Let me spell it out for you. The DOX reported in the tumour as a result of the peptide warhead was outright false information."

So then you are accusing the company, and everyone involved in reporting/verifying the results/RNS etc as outright lying/falsifying - and this (in your odd mind) is the same as 'promoting the business' and perfectly legal lol?

[rajraj b] 02/6/2024 21:27

PWhite-"The onus is on the company to provide independently verifiable evidence not me."I'm sorry but that is extremely poor on your part. The company has put out official RNS detailing these finding to the whole world. You, however, say they are untrue because it hasn't been independently verified. What evidence do you have that they are, as you say lying? Just because it hasn't been independently verified doesn't mean it's not true. You seem to be very sure about this with your innumerable posts going on about how it's all a lie. So let's have it. What have you got up your sleeve? What ace are you hiding that we're all oblivious to? If you're all waffle then stop wasting everyone's time with your unfounded accusations. Sad really, especially as you're not even invested here. Sad bordering on weird behaviour.

[pwhite73] 02/6/2024 19:42

Rajraj b - "I would like to know the evidence you have."

The onus is on the company to provide independently verifiable evidence not me.

I claim PW73 Hairgrow can cure baldness in men. The results I report show within two weeks of applying the PW73 cream hair follicles begin to appear in bald patches.

You can't disprove what I'm saying because I haven't provided any evidence to show you how PW Hairgrow at the molecular structural level causes hair follicles to regrow where there was none before. This is where you are with AVA6000. How does the peptide warhead release DOX when it comes into contact with FAP. Such a warhead would be worth £100s of millions in its own right before AVA6000 even enters Phase 2.


What I believe is that no such peptide warhead actually exists and that's the real reason they've teamed up with SOFIE. I can't be any clearer than that. I can't provide evidence to refute evidence that doesn't exist. I hope that makes sense.

[rajraj b] 02/6/2024 19:05

So let's get this right PWhite. You are saying that that AVCT have deliberately falsified their biopsy results which ( according to AVCT) have shown massive amounts of active Dox in the biopsy of tumours relative to plasma. You are also a saying that the collaboration that AVCT has sought with SOFIE is to do with some altogether new ( I don't even know how to clarify it according to you as it's so bizarre) form of drug investigation. Rather than them using SOFIE as a means to identify high FAPa sites using this technology i.e. a diagnostic/rapid visualisation aid. Please post some evidence relating to both assumptions as I would like to know the evidence you have. You seems to be very sure about all this so must have some pretty incriminating proof to back youself up.